Skip to content

Validation of Withings Sleep for the Detection of Sleep Apnea Syndrome

Validation of the Diagnostic Performance of the Withings Sleep Device in Detecting Sleep Apnea Syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04234828
Acronym
VPASS
Enrollment
200
Registered
2020-01-21
Start date
2019-07-03
Completion date
2026-12-31
Last updated
2026-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep Apnea Syndromes

Keywords

Sleep Apnea, Sleep Apnea Syndromes, Respiration Disorders, Respiratory Tract Diseases, Signs and Symptoms, Respiratory, Signs and Symptoms, Sleep Apnea, Obstructive, Sleep Disorders, Intrinsic, Dyssomnias, Sleep Wake Disorders, Nervous System Diseases, Apnea

Brief summary

Sleep Apnea Syndrome (SAS) is a common pathology affecting between 4 and 8% of the general population. It aggravates morbidity and cardio-metabolic mortality and is responsible for accidents related to vigilance disorders. It is estimated that 80% of SAS cases are not diagnosed and therefore not treated. It is however impracticable to propose a diagnostic test of polygraphy (PG) or polysomnography (PSG) to every patient because of the cost and insufficient availability of these exams. It would therefore be useful to carry out a screening test before directing the patient to a complete test. Several simplified polygraph systems with 2 or 3 channels have been proposed (nasal cannula, oximetry, heart rate) but they generally record only one night and remain intrusive enough to perturb the sleep. The Withings Sleep is a non-contact device, along with an airbag placed under the mattress, which allows screening of SAS from four signals: movement, breathing, heart rate and snoring. The objective of the present study is to validate the diagnostic performance of the Withings Sleep for the detection of SAS compared to PSG.

Interventions

None listed

Sponsors

Withings
Lead SponsorINDUSTRY

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* adults, men or women, aged between 18 and 70 * patients referred for an overnight polysomnographic exam for a suspicion of sleep-disordered breathing

Exclusion criteria

* children less than 18 years of age * patients treated with continuous positive airway pressure * person not giving her consent * vulnerable subject according to current regulation: * pregnant woman, parturient or breastfeeding * subject deprived of freedom by judicial, medical or administrative decision * subject legally protected or unable to express his consent * subject non-beneficiary of healthcare * subject falling into more than one of the above categories * subject in linguistic or psychic incapacity to express his consent

Design outcomes

Primary

MeasureTime frameDescription
Sensitivity and specificity of Withings Sleep at AHI threshold value of 30/h in PSGimmediately after interventionSensitivity and specificity for SAS detection by Withings Sleep compared to PSG at AHI threshold value of 30/h in PSG.
Sensitivity and specificity of Withings Sleep at AHI threshold value of 15/h in PSGimmediately after interventionSensitivity and specificity for SAS detection by Withings Sleep compared to polysomnography (PSG) at apnea-hypopnea index (AHI) threshold value of 15/h in PSG.

Secondary

MeasureTime frameDescription
Accuracy of Withings Sleep to estimate total sleep time (TST) given by PSGimmediately after interventionBias and mean absolute error (MAE)
Accuracy of Withings Sleep to estimate sleep efficiency (SE) given by PSGimmediately after interventionBias and MAE
Accuracy of Withings Sleep to estimate wake after sleep onset (WASO) given by PSGimmediately after interventionBias and MAE
Influence of the position of the sleeper (decubitus dorsal vs decubitus latero-ventral) on the error of the AHI predicted by Withings Sleep compared with PSGimmediately after interventionMean group difference between sleepers more than 50% of TST in decubitus dorsal or not.
Impact of the proportion of hypopnea events on the performance of Withings Sleepimmediately after interventionMean group difference between patients with a majority of apnea events and patients with a majority of hypopnea events.
Mean group difference between patients with central or mixed apnea and patients with obstructive apnea events.immediately after interventionMean group difference between patients with a majority of central or mixed apnea events and patients with a majority of obstructive apnea events.
Reliability of Withings Sleepimmediately after interventionRate of unusable or lost nights.
Sensitivity and specificity of polygraphy (PG)immediately after interventionSensitivity and specificity for SAS detection by polygraphy (PG) compared to PSG at AHI threshold values of 15/h in PSG.
Reliability of PSGimmediately after interventionRate of unusable or lost nights.
Sensitivity and specificity of PGimmediately after interventionSensitivity and specificity for SAS detection by PG compared to PSG at AHI threshold values of 30/h in PSG.

Countries

Belgium, France

Contacts

PRINCIPAL_INVESTIGATORGarbiel Roisman

Hôpital Antoine Béclère

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026